Novo Nordisk upgrades despite sales and bottom line disappointments in Q2

Following six months where analysts had hoped for stronger performance, the pharmaceutical giant has raised its sales growth guidance for full-year 2022 to 12–16%.

Photo: Novo Nordisk / PR

On Wednesday, Novo Nordisk surprised the market when it released its financial report for the first half of 2022 – the evening before it was scheduled to do so.

The Danish pharmaceutical giant disappointed on the bottom line compared to analysts’ high expectations, but the report still included a guidance upgrade for the full year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs